



May 17, 2016

## **Xencor to Present at Upcoming Investor Conferences**

MONROVIA, Calif., May 17, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:

- | **UBS Global Healthcare Conference**  
**Date:** Tuesday, May 24, 2016  
**Time:** 11:30 a.m. ET  
**Location:** New York, NY
- | **Jefferies 2016 Healthcare Conference**  
**Date:** Tuesday, June 7, 2016  
**Time:** 11:00 a.m. ET  
**Location:** New York, NY

Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, nine candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1a development for the treatment of asthma and allergic diseases; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300269291.html>

SOURCE Xencor, Inc.

News Provided by Acquire Media